Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.49 |
| ▸ | KIT | P10721 | 6/20 | 0.39 |
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18918802 | 0.94 | ULK1 (0.50) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18918668 | 0.93 | ULK1 (0.52) | ULK1KITLANCL2BRD4RIPK1 | |
| SCHEMBL18932436 | 0.91 | ULK1 (0.48) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18918803 | 0.90 | ULK1 (0.46) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18944196 | 0.88 | ULK1 (0.46) | ULK1KITLANCL2DDR1USP2 | |
| SCHEMBL18932435 | 0.88 | ULK1 (0.49) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18944192 | 0.88 | ULK1 (0.50) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18918898 | 0.88 | ULK1 (0.45) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18932437 | 0.87 | ULK1 (0.47) | ULK1KITLANCL2USP2CYP1A2 | |
| SCHEMBL18932432 | 0.87 | ULK1 (0.49) | ULK1KITLANCL2USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | claimed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | claimed |
| EP-3386980-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP3K13, WEE2 | ULK1 495/4885KIT 1525/4885LANCL2 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.